Ipsen

Ipsen Graham Number

The Graham Number of Ipsen (IPN.PA) as of Nov 6, 2026 is 79.55 EUR. In the previous year, Graham Number was 68.47 EUR — a change of 16.18% (higher).

Graham Number

79.55EUR

YoY

16.18%

Last updated:

Graham Number of Ipsen is 2025 79.55 EUR. Graham Number of Ipsen was 2024 68.47 EUR. It decreases by 16.18% higher compared to the previous year.

The Ipsen Graham Number history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Graham Number
Date
Graham Number
Jan 1, 2017
36.70 EUR
Jan 1, 2018
48.14 EUR
Jan 1, 2020
61.45 EUR
Jan 1, 2021
75.85 EUR
Jan 1, 2022
83.89 EUR
Jan 1, 2023
89.25 EUR
Jan 1, 2024
68.47 EUR
Jan 1, 2025
79.55 EUR
The Ipsen Graham Number history
YEARGraham NumberYoY
79.55EUR+16.18%
68.47EUR-23.28%
89.25EUR+6.39%
83.89EUR+10.60%
75.85EUR+23.43%
61.45EUR+27.65%
48.14EUR+31.17%
36.70EUR+15.90%
31.66EUR+15.07%
27.52EUR+18.83%
23.16EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Graham Number of Ipsen is 79.55 EUR in 2025.

On Eulerpool you can find the complete historical development of Graham Number Ipsen since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Ipsen

All Key Metrics — Ipsen